{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:12:14Z","timestamp":1791396734105,"version":"4.3.3"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamapsychiatry.2019.4379","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T11:01:47Z","timestamp":1578481307000},"page":"349","source":"Crossref","is-referenced-by-count":125,"title":["Efficacy and Safety of Lumateperone for Treatment of Schizophrenia"],"prefix":"10.1001","volume":"77","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Davis","sequence":"additional","affiliation":[{"name":"Intra-Cellular Therapies Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Weingart","sequence":"additional","affiliation":[{"name":"Intra-Cellular Therapies Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Saillard","sequence":"additional","affiliation":[{"name":"Intra-Cellular Therapies Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"O\u2019Gorman","sequence":"additional","affiliation":[{"name":"Intra-Cellular Therapies Inc, New York, New York"},{"name":"Now with Axsome Therapeutics Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Tamminga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mates","sequence":"additional","affiliation":[{"name":"Intra-Cellular Therapies Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Vanover","sequence":"additional","affiliation":[{"name":"Intra-Cellular Therapies Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi190095r1","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia.","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"yoi190095r2","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 study.","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob Health"},{"key":"yoi190095r3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"9896","key":"yoi190095r4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"yoi190095r5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.v14.2","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"12","key":"yoi190095r6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States.","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yoi190095r7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.v16.2","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"issue":"4","key":"yoi190095r8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"yoi190095r9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes.","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"yoi190095r10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"yoi190095r11","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics.","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"yoi190095r15","first-page":"97","article-title":"The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling.","volume":"24","author":"Overall","year":"1988","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"yoi190095r17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"6","key":"yoi190095r18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/JCP.0b013e31818c9ba3","article-title":"Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia.","volume":"28","author":"Shen","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi190095r19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","article-title":"Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.","volume":"30","author":"Kobak","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi190095r20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1185\/03007990802611919","article-title":"Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.","volume":"25","author":"Patrick","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"yoi190095r21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/00005053-200010000-00003","article-title":"Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders.","volume":"188","author":"Purnine","year":"2000","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"yoi190095r22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics.","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr Res"},{"key":"yoi190095r23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/acp.1970.45.issue-s212","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"5","key":"yoi190095r24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"12","key":"yoi190095r25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi190095r26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/bimj.v50:5","article-title":"General multistage gatekeeping procedures.","volume":"50","author":"Dmitrienko","year":"2008","journal-title":"Biom J"},{"issue":"13","key":"yoi190095r27","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/sim.v30.13","article-title":"Mixtures of multiple testing procedures for gatekeeping applications in clinical trials.","volume":"30","author":"Dmitrienko","year":"2011","journal-title":"Stat Med"},{"issue":"4","key":"yoi190095r28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1080\/10543406.2015.1074917","article-title":"Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypotheses.","volume":"26","author":"Dmitrienko","year":"2016","journal-title":"J Biopharm Stat"},{"issue":"12","key":"yoi190095r29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial.","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"10","key":"yoi190095r30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors.","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"10202","key":"yoi190095r31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"yoi190095r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors.","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry"},{"key":"yoi190095r33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.psychres.2019.02.021","article-title":"Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.","volume":"274","author":"Correll","year":"2019","journal-title":"Psychiatry Res"},{"issue":"11-12","key":"yoi190095r34","first-page":"18","article-title":"Using the positive and negative syndrome scale (PANSS) to define different domains of negative symptoms: prediction of everyday functioning by impairments in emotional expression and emotional experience.","volume":"14","author":"Harvey","year":"2017","journal-title":"Innov Clin Neurosci"},{"issue":"3","key":"yoi190095r35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia.","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi190095r36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation.","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"yoi190095r37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4088\/JCP.9089pi3cc","article-title":"What are we looking for in new antipsychotics?","volume":"72","author":"Correll","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi190095r38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"yoi190095r39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/wps.v12.3","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls.","volume":"12","author":"Vancampfort","year":"2013","journal-title":"World Psychiatry"},{"issue":"3","key":"yoi190095r40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"2","key":"yoi190095r41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry"},{"issue":"3","key":"yoi190095r42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.v12.3","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"yoi190095r43","first-page":"1","article-title":"Seizure rates under treatment with antipsychotic drugs: Data from the AMSP project.","author":"Druschky","year":"2018","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"yoi190095r44","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.4088\/JCP.15m09898","article-title":"Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders.","volume":"77","author":"Wu","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"yoi190095r45","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1093\/schbul\/sby018.831","article-title":"Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study.","volume":"44","author":"Vanover","year":"2018","journal-title":"Schizophr Bull"},{"key":"yoi190095r12","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi190095r13","volume-title":"Structured clinical interview for DSM-IV-TR Axis I disorders, clinical trials version (SCID-CT)","author":"First","year":"2007"},{"key":"yoi190095r14","volume-title":"Structured Clinical Interview for DSM-5 Disorders\u2014Clinical Trials Version (SCID-5-CT, Modified for ITI-007-301)","author":"First","year":"2014"},{"key":"yoi190095r16","volume-title":"ECDEU Assessment Manual for Psychopharmacology","year":"1976"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2758022\/jamapsychiatry_correll_2020_oi_190095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T11:01:19Z","timestamp":1585738879000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2758022"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.4379","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}